Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca's Enhertu Cancer Treatment Reduced Risk of Disease Progression by 72%

09/20/2021 | 12:33am EDT

By Anthony O. Goriainoff

AstraZeneca PLC said Monday that its cancer treatment Enhertu reduced the risk of disease progression or death by 72% in patients with HER2-positive metastatic breast cancer.

HER2 refers to a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2.

The U.K. pharmaceutical giant said that the DESTINY-Breast03 Phase 3 trial showed that Enhertu demonstrated superior progression-free survival versus trastuzumab emtansine, a HER2-directed antibody drug conjugate currently approved to treat patients with HER2-positive unresectable--unable to be removed by surgery--and/or metastatic breast cancer previously treated with trastuzumab and a taxane--a type of drug that blocks cell growth.

"The high and consistent benefit seen across efficacy endpoints and key subgroups of patients receiving Enhertu in DESTINY-Breast03 is remarkable and supports the potential of Enhertu to become the new standard of care for those who have previously been treated for HER2-positive metastatic breast cancer," the company said.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

09-20-21 0233ET

All news about ASTRAZENECA PLC
10/19ASTRAZENECA : WHO-led programme aims to buy antiviral COVID-19 pills for $10 -document
RE
10/19MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
10/19MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
10/19ASTRAZENECA : Scientists behind AstraZeneca/Oxford vaccine work on Delta-specific jab
AQ
10/19MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
10/19ASTRAZENECA : UBS maintains a Buy rating
MD
10/19ASTRAZENECA : India delays COVID-19 vaccine supplies to WHO-backed COVAX, sources say
RE
10/19PFIZER : Federal COVID vaccine compensation up to $20,000
AQ
10/18ADRs End Mixed; Valneva, IClick Among Companies Actively Trading
DJ
10/18ASTRAZENECA : recommends shareholders reject 'Mini-Tender' Offer by TRC Capital Investment..
PU
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 457 M - -
Net income 2021 4 915 M - -
Net Debt 2021 24 833 M - -
P/E ratio 2021 34,4x
Yield 2021 2,34%
Capitalization 187 B 187 B -
EV / Sales 2021 5,97x
EV / Sales 2022 4,84x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 120,53 $
Average target price 137,75 $
Spread / Average Target 14,3%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC19.32%184 835
JOHNSON & JOHNSON4.12%421 513
ROCHE HOLDING AG17.78%342 644
NOVO NORDISK A/S56.38%238 110
PFIZER, INC.12.25%231 668
ELI LILLY AND COMPANY43.51%216 655